AstraZeneca Drug Extends Survival in Advanced Gastric Cancer
WILMINGTON, DE — AstraZeneca’s experimental antibody-drug conjugate sonesitatug vedotin improved overall survival in a Phase III trial of previously treated CLDN18.2-positive advanced gastric and related cancers, potentially broadening targeted treatment …
AstraZeneca Drug Extends Survival in Advanced Gastric Cancer Read More